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Introduction
Nonalcoholic fatty liver disease (NAFLD) and nonalcoholic 
steatohepatitis (NASH) are now the most common causes of liver 
disease in Western countries (1). NAFLD-induced liver failure is 
one of the most common reasons for liver transplantation. NAFLD 
increases the risk of developing type 2 diabetes, worsens glycemic 
control, and contributes to the pathogenesis of cardiovascular 
disease and chronic kidney disease (2–4). The pathogenic mech-
anisms of NAFLD and NASH are incompletely understood but 
are thought to involve abnormalities of hepatocyte metabolism, 
hepatocyte autophagy and endoplasmic reticulum stress, hepatic 
immune cell function, adipose tissue inflammation, and systemic 
inflammatory mediators (2, 4–6). Perturbations of carbohydrate, 
lipid, and amino acid metabolism occur in and contribute to obe-
sity, diabetes, and NAFLD in humans and in model organisms 
(reviewed in refs. 7–11). While hepatocyte abnormalities in cyto-
plasmic lipid metabolism are commonly observed in NAFLD (12), 
the role of mitochondrial metabolism, which governs the oxida-
tive and terminal “disposal” of fats, in NAFLD pathogenesis is less 
clear. Nonetheless, most investigators agree that abnormalities 
of mitochondrial metabolism occur in and contribute to NAFLD 
(reviewed in refs. 13–15).
Ketogenesis can dispose of as much as two-thirds of the fat 
entering the liver (16). Thus, dysregulation of ketone body metabo-
lism could potentially contribute to NAFLD pathogenesis. Hepatic 
ketogenesis is activated in states of high fatty acid and diminished 
carbohydrate availability and/or when circulating insulin concen-
trations are very low (17–20). Within hepatic mitochondria, keto-
genic reactions condense β-oxidation–derived acetyl-CoA into the 
ketone bodies acetoacetate (AcAc) and β hydroxybutyrate (βOHB). 
In doing so, ketogenesis disposes of acetyl-CoA generated in 
excess of the liver’s own energy needs and simultaneously recycles 
2 moles of free coenzyme A (CoASH) per mole of ketone produced 
(reviewed in refs. 17, 19, 20). Robust ketogenesis is limited to hepa-
tocytes due to relatively restricted expression of the fate-commit-
ting ketogenic enzyme mitochondrial 3-hydroxymethylglutaryl- 
CoA synthase (HMGCS2) under normal conditions (21). In 
contrast, oxidative disposal of ketone bodies is nearly ubiquitous, 
as all cells except hepatocytes express the fate-committing enzyme 
of ketone body oxidation succinyl-CoA:3-oxoacid CoA transfer-
ase (SCOT) (22, 23). Within the mitochondria of extrahepatic tis-
sues, βOHB is oxidized to AcAc, which is then directed toward the 
TCA cycle for terminal oxidation via a reaction uniquely catalyzed 
by SCOT (17). Despite its high capacity as a disposal pathway for 
hepatic fatty acids, ketone body metabolism has been overlooked 
as a potential therapeutic target in NAFLD.
Through incompletely defined mechanisms, obesity-associ-
ated hyperinsulinemia suppresses ketogenesis, creating a state 
of relative ketogenic insufficiency and leading to hypoketonemia 
in obese animal models and humans when compared with lean 
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with this article; doi:10.1172/JCI76388DS1). Intriguingly, this par-
tial loss of ketogenesis was associated with a nearly 7-fold increase 
in hepatic triacylglycerol (TAG) concentrations (6.6 ± 1.2 mg/g 
vs. 0.96 ± 0.2 mg/g tissue in controls, n = 4–6/group, P < 0.001; 
Figure 1C). To determine whether HMGCS2-mediated ketogene-
sis plays a role in a model of adult NAFLD, we administered i.p. 
injections of HMGCS2 ASO (25 mg/kg biweekly for 4 weeks) into 
C57BL/6 male mice maintained on a standard low-fat chow diet. 
After 4 weeks, we found that hepatic Hmgcs2 transcript abundance 
was decreased by 88% compared with that in mice treated with 
control ASO (n = 8–10 per group, P < 0.001), without diminish-
ing the scant Hmgcs2 transcript abundance normally observed 
in s.c. adipose tissue (ref. 30 and Supplemental Figure 1, C and 
D). Immunoreactive HMGCS2 was eliminated from the liver in 
HMGCS2 ASO–treated mice (Figure 1D). ASO treatment did not 
diminish the protein abundance of cytoplasmic 3-hydroxymeth-
ylglutaryl-CoA synthase (HMGCS1), which catalyzes the penulti-
mate reaction in mevalonate synthesis (Supplemental Figure 1E).
HMGCS2 ASO–treated mice exhibited markedly blunted 
ketonemia in both baseline (fed) and nutrient-deprived states (Fig-
ure 1E). To confirm the inability of HMGCS2 ASO–treated mice 
to effectively incorporate fatty acid–derived carbon into ketone 
bodies, livers from control and HMGCS2 ASO–treated mice were 
perfused ex vivo via the portal vein with an oxygenated buffer 
containing the fatty acid [13C]octanoic acid. Quantitative mapping 
controls (24–29). To test the hypothesis that impaired ketogene-
sis, even in carbohydrate-replete and thus “nonketogenic” states, 
contributes to abnormal glucose metabolism and provokes steato-
hepatitis, we generated a mouse model of marked ketogenic 
insufficiency and used complementary systems physiological 
approaches and 13C-labeling–based high-resolution measures of 
metabolic dynamics to characterize the wide-ranging effects of 
ketogenic impairment.
Results
Ketogenic insufficiency causes abnormal hepatic glucose and lipid 
metabolism. The ability of ketogenesis to influence hepatic glucose 
and lipid homeostasis has only been preliminarily characterized. 
To determine the consequences of impaired ketogenesis during 
the highly ketogenic neonatal period, suckling mice were injected 
s.c. (25 mg/kg) with an Hmgcs2-targeted antisense oligonucleo-
tide (ASO) daily, beginning on the second day of extrauterine life. 
Compared with littermates injected with scrambled sequence 
control ASO, we found that HMGCS2 ASO treatment decreased 
hepatic HMGCS2 protein abundance by 70% by postnatal day 
12 (P12) (Figure 1A). These mice exhibited normal body weights 
and blood glucose concentrations and displayed mildly decreased 
plasma ketone body concentrations (0.9 ± 0.05 mM vs. 1.3 ± 0.17 
mM in controls, n = 4–6/group, P < 0.05; Figure 1B and Supple-
mental Figure 1, A and B; supplemental material available online 
Figure 1. Ketogenic insufficiency in mice treated with HMGCS2 ASO. (A) Immunoblot for HMGCS2 and actin using protein lysates derived from livers 
of neonatal mice treated with either a scrambled sequence control ASO or HMGCS2 ASO. Mice were treated with ASO daily for 11 days, beginning on the 
second day of life, and tissues and serum were collected on P12. Normalized protein abundance is quantified below. (B) Serum total ketone body (TKB) 
concentrations (mM) and (C) hepatic TAG concentrations (mg/g tissue) on P12 in ASO-treated mice n = 4–6/group. (D) Immunoblot for HMGCS2 and actin 
using protein lysates derived from the livers of adult mice treated with control or HMGCS2 ASO biweekly for 4 weeks beginning at 6 weeks of age. (E) 
Serum TKB concentrations (mM) during fasting in adult mice treated with ASOs for 4 weeks. n = 3–5/group. *P < 0.05, ***P < 0.001 by Student’s t test 
versus HMGCS2 ASO–treated mice, or as indicated.
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livers of these mice exhibit impaired ketogenesis, i.e., are keto-
genesis insufficient (Supplemental Figure 1F). Despite exhibiting 
marked ketogenic impairment, we observed that HMGCS2 ASO–
treated mice fed a standard low-fat chow diet did not differ in body 
weight, body composition, or food intake compared with control 
of the 13C-label using 13C-edited proton NMR profiling (31–34) 
revealed markedly blunted incorporation of the label into βOHB in 
HMGCS2 ASO–treated mice in both the fed and overnight-fasted 
states. These results confirm that HMGCS2 is required for effec-
tive derivation of ketone bodies from fatty acids and indicate that 
Figure 2. Hepatic injury in HFD-fed ketogenesis-insufficient mice. (A) Hepatic TAG concentrations (mg/g tissue) and (B) serum ALT activity (U/l) in 
ASO-treated mice fed a standard low-fat chow diet (Chow) for 4 weeks or an HFD for 8 weeks; n = 4–5/group. (C) Representative H&E-stained sections of 
liver from ASO-treated mice fed the indicated diet. Arrowheads indicate dying hepatocytes (acidophil bodies). Scale bars: 50 μm and 100 μm (bottom left 
panel). (D) Representative ×20 fields showing immunostaining for F4/80+ and (E) SMA+ cells in cryosections of liver from ASO-treated mice fed an HFD for 
8 weeks. Quantification for each is shown on the right. n = 5 random ×20 fields/liver and 19 random ×10 fields/liver, respectively (n = 3 animals/group).  
**P < 0.01, ***P < 0.001 by Student’s t test or 2-way ANOVA.
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Ketogenic insufficiency causes hepatic inflammation, injury, and 
altered glucose metabolism in the setting of carbohydrate-replete over-
nutrition. To determine the effects of ketogenic insufficiency in 
the context of overnutrition, mice previously receiving ASOs for 2 
weeks while on a standard low-fat chow diet were then maintained 
for 8 weeks on a 60% high-fat diet (HFD) commonly used to 
induce hyperglycemia, hepatic steatosis, and inflammation in WT 
mice. HMGCS2 immunoblots indicated that hepatic HMGCS2 
mice (Supplemental Figure 2, A–C). HMGCS2 ASO–treated mice 
also exhibited normal serum free fatty acid (FFA) and TAG concen-
trations and a normal physiologic distribution of residual βOHB 
and AcAc (Supplemental Figure 2, D–F). Interestingly, HMGCS2 
ASO–treated mice displayed mild, but very consistently elevated, 
blood glucose concentrations (160.9 ± 3.2 mg/dl vs. 145.0 ± 3.4 
mg/dl in controls, n = 28–36/group, P = 0.0013), without changes 
in serum insulin concentrations (Supplemental Figure 2, G and H).
Figure 3. Diminished glycemia and hepatic gluconeogenesis in HFD-fed ketogenesis-insufficient mice. (A) Blood glucose (mg/dl) and (B) percentage of 
basal blood glucose in ASO-treated mice beginning at the onset of 60% HFD feeding. n = 8–10/group. (C) Body weight  and (D) caloric intake (kcal/mouse/
day) during 60% HFD maintenance and ASO treatment. n = 8–10/group. ***P < 0.001 by linear regression t test. (E) Quantification of fractional 13C enrich-
ment of glucose from [13C]pyruvate (a surrogate for gluconeogenesis) determined by 13C-edited proton NMR spectroscopy in liver extracts of 60% HFD-fed 
ASO-treated mice perfused via the portal vein with [13C]lactate and [13C]pyruvate in a physiological ratio. n =4–5/group. (F) Total hepatic glucose concentra-
tion (pmol/mg tissue) and (G) moles of 13C-glucose produced from [13C]lactate and [13C]pyruvate, quantified by NMR profiling of perfused liver extracts from 
ASO-treated mice fed a 60% HFD for 8 weeks. n = 4–5/group. *P < 0.05, **P < 0.01, ***P < 0.001 by Student’s t test.
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matory infiltrates and acidophil bodies (dying hepatocytes). We 
did not observe these findings in livers from HFD-fed control 
ASO-treated mice or chow-fed HMGCS2-deficient mice (Figure 
2C). Livers of HFD-fed HMGCS2 ASO–treated mice also exhib-
ited increased numbers of sinusoidal macrophages, as confirmed 
by F4/80 immunohistochemical staining (80.5 ± 6.1 vs. 49.3 ± 3.2 
F4/80+ cells/×20 field, P < 0.001, n = 5 fields/liver from 3 livers/
group; Figure 2D), and increased evidence of stellate cell activa-
tion, as indicated by anti–smooth muscle actin (SMA) immunos-
taining (8.2 ± 1.0 vs. 3.4 ± 0.6 SMA+ cells/×10 field, P < 0.001, 
n = 19 fields/liver from 3 livers/group; Figure 2E). These results 
indicate that ketogenic insufficiency in the setting of overnutrition 
accelerates a pronounced NASH-like phenotype.
To determine the metabolic effects of ketogenic insufficiency 
in the setting of overnutrition, we monitored blood glucose con-
centrations during the course of HFD administration. While 
blood glucose levels were higher in HMGCS2 ASO–treated 
mice at the onset of HFD feeding, glycemia began to decline in 
these mice after 5 weeks of maintenance on this diet (Figure 3, 
A and B). HFD-fed HMGCS2 ASO–treated mice also gained sig-
nificantly less weight than did control mice (final weight after 
HFD feeding: 26.8 ± 0.7 g vs. 30.3 ± 1.2 g in controls, P = 0.019, 
n = 8–10/group) and ingested fewer calories (9.96 ± 0.3 kcal/
mouse/day vs. 12.9 ± 0.3 kcal/mouse/day in controls, P < 0.0001, 
protein abundance was decreased by 93% within 2 weeks of ASO 
treatment (Supplemental Figure 3A) and continued to decrease to 
undetectable levels by the end of the 8-week HFD-feeding interval, 
during which time ASO treatments were continued on a biweekly 
basis (Supplemental Figure 3B). While serum TAG and FFA con-
centrations did not differ between groups of HFD-fed mice (Sup-
plemental Figure 3, C and D), serum ketone body concentrations 
were significantly decreased in HFD-fed HMGCS2 ASO–treated 
mice (0.04 ± 0.02 mM vs. 0.26 ± 0.03 mM, P < 0.0001, n = 8–10/
group; Supplemental Figure 3E). After 8 weeks of HFD feeding, 
we found that control and HMGCS2 ASO–treated mice exhib-
ited mildly increased hepatic TAG concentrations (Figure 2A). 
As expected, serum alanine aminotransferase (ALT) activity, a 
circulating biomarker of hepatocellular injury, was not elevated 
in HFD-fed control mice, given the relatively brief duration of 
the HFD (Figure 2B). Conversely, HFD feeding increased serum 
ALT activity by nearly 4-fold in HMGCS2 ASO–treated mice com-
pared with mice maintained on a standard chow diet (223.5 ± 37.7 
U/l vs. 61.2 ± 4.0 U/l in chow-fed HMGCS2 ASO–treated mice, 
n = 4–5/group, P < 0.0001) and by 3-fold compared with the HFD-
fed control mice (223.5 ± 37.7 U/l vs. 74.3 ± 6.1 U/l in control mice, 
n = 4/group, P < 0.0001; Figure 2B). Blinded histopathologic 
evaluation of liver tissue from ketogenesis-insufficient mice fed 
an HFD revealed evidence of injury, including panacinar inflam-
Figure 4. Mitochondrial acetyl-CoA and short- and medium-chain acylcarnitine accumulation in ketogenesis-insufficient mice. Mitochondrial respira-
tion determined by the oxygen consumption rate of isolated mitochondria. State 2 (basal), state 3 (ADP), state 4 (oligomycin), and uncoupled (FCCP) res-
piration of mitochondria isolated from the livers of standard chow diet–fed ASO-treated mice using either (A) 10 mM pyruvate alone or (B) 10 mM pyruvate 
with 5 mM malate as an anaplerotic substrate. n = 6–9/group. Blood acylcarnitines (μM) in (C) 40% and (D) 60% HFD-fed ASO-treated mice, determined by 
MS/MS. n = 4–10/group. *P < 0.05, **P < 0.01, ***P < 0.001, by Student’s t test.
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n = 8–10 mice/group over 16 measurements of food intake; 
Figure 3, C and D). However, decreased glycemia in ketogene-
sis-insufficient mice was not entirely attributable to decreased 
caloric intake, because the capacity to support de novo glucose 
production from [13C]pyruvate was decreased 4-fold in perfused 
livers of HFD-fed HMGCS2 ASO–treated mice (1.8 ± 0.3% vs. 
7.3 ± 1.1% fractional enrichment as [13C]glucose in controls, 
P = 0.0009, n = 4–5/group; Figure 3E). While the total hepatic 
glucose pool was expanded in perfused livers of HFD-fed 
HMGCS2 ASO–treated mice (Figure 3F), de novo 13C-label-
ing of glucose from [13C]pyruvate was markedly diminished in 
HFD-fed HMGCS2 ASO–treated livers (3.9 ± 1.7 pmol vs. 10.4 
± 0.9 pmol [13C]glucose produced/mg of tissue in controls, 
P = 0.016, n = 4–5/group; Figure 3G). Similarly to the responses 
to the 60% HFD, HMGCS2 ASO–treated mice maintained on a 
distinct 40% fat/sucrose-enriched diet for 8 weeks also exhib-
Figure 5. Altered DNL signatures in ketogenesis-insufficient mice. (A) Transcript abundances of DNL mediators in livers from ASO-treated mice. n = 5–10/
group. Srebp1c, sterol regulatory element–binding protein 1c; Chrebp1, carbohydrate-responsive element-binding protein 1; Fasn, fatty acid synthase; Acc1, 
acetyl-CoA carboxylase; Scd1 and Scd2, stearoyl-CoA desaturase 1 and 2. (B) XCMS Online cloud plot of 495 dysregulated features in HMGCS2 ASO–treated liv-
ers perfused with [13C]pyruvate and [13C]lactate compared with those of control livers. The radius (upregulated and downregulated features relative to controls 
are green and red, respectively) and shading darkness of each circle are proportional to each circle’s fold-change and P value, respectively. n = 4/group.  
(C) Schematic adapted from the KEGG (refs. 38, 39), depicting the 14- and 16-carbon-long intermediates produced during fatty acid synthesis. Species puta-
tively identified as features that are significantly enriched in HMGCS2 ASO–perfused livers are highlighted in green. (D) Untargeted LC/MS metabolomics iden-
tification and quantification of total abundance of long-chain acyl-CoA species in the livers of ASO-treated mice perfused with [13C]pyruvate and [13C]lactate.  
n = 4/group. (E) Quantification of fractional 13C enrichment of glutamate from [13C]pyruvate determined by NMR in extracts of perfused livers of ASO-treated 
mice. n = 7–8/group. (F) Relative acetyl-CoA ion counts in the livers of ASO-treated mice perfused with lactate and pyruvate as measured by LC/MS.  
n = 4/group. *P < 0.05, **P < 0.01, ***P < 0.001 by Student’s t test or 2-way ANOVA, as appropriate, versus HMGCS2 ASO–treated mice, or as indicated.
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ited decreased weight gain, caloric intake, body fat percent-
ages, and blood glucose concentrations (Supplemental Figure 
4, A–D). Ketogenesis-insufficient mice fed a 40% HFD also exhib-
ited hepatic steatosis equivalent to that of control HFD-fed mice, 
modestly increased serum ALT activity, and microgranuloma for-
mation and inflammatory infiltrates in the liver (Supplemental Fig-
ure 5, A–C). Importantly, we found that both the elevation of serum 
ALT activity and the degree of histopathologic evidence of hepatic 
inflammation were diminished in HMGCS2 ASO–treated mice fed 
a 40% HFD compared with those fed a 60% HFD, suggesting that 
chronic exposure to excess dietary fat drives the NASH-like pheno-
type observed in ketogenesis-insufficient mice.
Figure 6. Hepatic metabolic reprogramming in ketogenesis-insufficient mice. (A) Quantification of 13C enrichment of glucose from [13C]pyruvate and total 
glucose concentrations (pmol/mg tissue) (B) determined by NMR in liver extracts of standard chow diet–fed ASO-treated mice perfused with the indicated 
substrates. n = 7–8/group. (C) Relative transcript abundances of key mediators of fatty acid oxidation and gluconeogenesis in livers from standard chow 
diet–fed ASO-treated mice. n = 8–10/group. Ppara, peroxisome proliferator–activated receptor α; Ppargc1a, peroxisome proliferator–activated receptor γ 
coactivator 1-α; Acox1, acyl-CoA oxidase; Cpt1a, carnitine palmitoyl transferase 1-α; Acadm, medium-chain acyl-CoA dehydrogenase; Fgf21, fibroblast growth 
factor 21; Me2, malic enzyme 2; Pck1, phosphoenol pyruvate carboxykinase; G6pc, glucose-6-phosphatase. (D) Quantification of total α-KG (nmol/mg tissue), 
(E) succinate (pmol/mg tissue), and (F) total glutamate concentrations (nmol/mg tissue) determined by NMR in liver extracts of standard chow diet–fed 
ASO-treated mice perfused with the indicated substrates. n = 7–8/group. (G) Concentrations of oxidized, reduced, and total nicotinamide adenine dinucleo-
tide (NAD+, NADH, and NADt, respectively; nmol/g tissue) as well as the ratio of NAD+/NADH levels in the livers of standard chow diet–fed ASO-treated mice 
perfused with lactate and pyruvate or (H) with lactate and pyruvate in the presence of octanoic acid. n = 4–6/group. *P < 0.05, **P < 0.01, ***P < 0.001 by 
Student’s t test or 2-way ANOVA, as appropriate, versus HMGCS2 ASO–treated mice, or as indicated.
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experiments to test the hypothesis that insufficient ketogenesis 
stimulates the procession of acetyl-CoA through the latter 3 non-
ketogenic pathways. First, to determine whether the acetyl-CoA 
fate was altered in hepatic mitochondria of ketogenesis-insuffi-
cient mice, we performed respiration studies on isolated hepatic 
mitochondria from ASO-treated animals fed a standard low-fat 
chow diet. While respiration rates using fatty acids (palmitoyl-L-
carnitine or octanoate) as oxidative substrates were not impaired 
Ketogenic insufficiency increases acyl-CoA synthesis. Abnormal 
hepatic glucose metabolism in HFD-fed ketogenesis-insufficient 
animals suggested reprogramming of intermediary metabolism. 
Because the major conduits for acetyl-CoA in hepatic mitochon-
dria include: (a) ketogenesis, (b) transport to the cytoplasm via 
the citrate shuttle to serve as a substrate for sterol or fatty acid 
synthesis, (c) terminal oxidation in the TCA cycle, or (d) ultimate 
conversion to acetylcarnitine (19), we performed 3 independent 
Figure 7. Replenishing CoASH precursors restores gluconeogenesis and TCA cycle intermediate abnormalities in the livers of ketogenesis-insufficient 
mice. (A) CoASH (pmol/mg tissue) concentrations in the livers of unperfused standard chow diet–fed ASO-treated mice or in livers perfused with the indi-
cated substrates. n = 3–8/group. (B) Pantothenate kinase 1a and 1b (Pank1a and Pank1b) relative mRNA abundance in the livers of standard chow diet–fed 
ASO-treated mice. n = 8–10/group. (C) Gluconeogenesis in perfused livers of standard chow diet–fed ASO-treated mice perfused with either [13C]lactate, 
[13C]pyruvate, octanoic acid, cysteine, and pantothenic acid for 15 minutes (Preperfusion–) or preperfused with CoASH precursors for 45 minutes with 
unlabeled lactate, pyruvate, cysteine, and pantothenic acid followed by 15 minutes of perfusion with [13C]lactate, [13C]pyruvate, octanoic acid, cysteine, and 
pantothenic acid. (D) α-KG (nmol/mg tissue), (E) glutamate (nmol/mg tissue), (F) succinate (pmol/mg tissue), and (G) CoASH (pmol/mg tissue) concentra-
tions in the same livers as in C. n = 5–7/group. *P < 0.05, **P < 0.01, ***P < 0.001, by 2-way ANOVA.
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of the TCA cycle to dispose of them. Nonetheless, carnitine esters 
provide another mechanism for short- and medium-chain acyl-
CoA disposal through nonketogenic mechanisms.
A third line of investigation comprehensively profiled the fate 
of acetyl-CoA in an unbiased manner. mRNA abundances of key 
encoded mediators of de novo lipogenesis (DNL) were increased in 
the livers of ketogenesis-insufficient animals, including significant 
increases in Srebp1c, Chrebp1, and Scd2, and strong trends toward 
increases in Fasn and Acc1 (Figure 5A). To map the full scope of the 
metabolic fates of acetyl-CoA, we perfused the livers of standard 
chow diet–fed ketogenesis-insufficient and control animals with a 
buffer containing [13C]pyruvate (and its redox partner [13C]lactate) 
for 15 minutes and analyzed extracts of these samples with a liquid 
chromatography/mass spectrometry-based (LC/MS-based) untar-
geted metabolomics platform (36, 37). We used [13C]pyruvate to 
generate a mitochondrial pool of labeled [13C]acetyl-CoA, whose 
downstream fates could then be assayed by detecting 13C enrich-
ment in metabolites using LC/MS, comparing metabolite abun-
dances in ketogenesis-insufficient animals versus those in controls. 
This analysis revealed that ketogenic insufficiency in the livers of 
mice fed a standard chow diet resulted in altered levels of 495 fea-
tures (i.e., peaks in the LC/MS data) of a total of 35,506 detected 
(fold-change >20, P value < 0.01; Figure 5B and Supplemental 
Table 4). Remarkably, all but 3 of these 495 features were upreg-
ulated in the livers from ketogenesis-insufficient mice relative to 
those detected in control livers, suggesting that the vast majority 
of revealed features can be attributed to alterations of metabolite 
pool sizes rather than the emergence of new fates for [13C]pyruvate.
Given the alterations we identified in mRNAs of DNL medi-
ators, metabolites in the fatty acid elongation pathway were of 
particular interest. Thus, we searched all features of 13C-labeled 
in hepatic mitochondria isolated from ketogenesis-insufficient 
animals (data not shown), oxygen consumption using pyruvate 
alone was markedly impaired: respiratory rates were diminished 
31% in state 2 (basal proton leak), 62% in state 3 (ADP-stimulated), 
49% in state 4 (ATP synthase–inhibited), and 65% during uncou-
pled (maximal) respiration (Figure 4A). These results suggested 
relatively impaired pyruvate oxidation in ketogenesis-insufficient 
mice. Pyruvate dehydrogenase (PDH), the enzyme that decar-
boxylates pyruvate to form acetyl-CoA for terminal oxidation in 
the TCA cycle, is inhibited by increased acetyl-CoA concentra-
tions (35). The addition of anaplerotic malate, which can facili-
tate acetyl-CoA export as citrate upon its conversion to oxaloac-
etate, normalized the capacity of hepatic mitochondria isolated 
from ketogenesis-insufficient mice to oxidize pyruvate (Figure 
4B). Independent respiration studies using malate alone revealed 
minimal oxygen consumption that did not differ between groups 
(data not shown). These results suggest that while the respiratory 
function of isolated mitochondria from ketogenesis-insufficient 
mice is intact, an anaplerotic substrate is required to facilitate 
cytoplasmic export of excess acetyl-CoA as citrate to relieve inhi-
bition of pyruvate oxidation.
Second, we quantified circulating acylcarnitine concentra-
tions and observed that short- and medium-chain acylcarnitine 
concentrations, but not those of long-chain acylcarnitines, were 
significantly increased in HMGCS2 ASO–treated mice compared 
with controls fed either a 40% or 60% HFD, but not a standard 
low-fat chow diet (Figure 4, C and D; See Supplemental Tables 
1–3 for full acylcarnitine profiles for chow-fed, 40% HFD-fed, and 
60% HFD-fed mice). These results suggest that ketogenic insuf-
ficiency is unlikely to cause an overt impairment of β-oxidation, 
but that the supply of short-chain acyl-CoAs exceeds the capacity 
Figure 8. Model of hepatic maladaptation to ketogenic insufficiency. Under homeostatic conditions (left panel), mitochondrial acetyl-CoA can be chan-
neled to ketogenesis, terminal oxidation in the TCA cycle, or exported to the cytoplasm for DNL. In the setting of ketogenic insufficiency (middle panel), DNL 
and gluconeogenesis from pyruvate are increased. Loss of the ketogenic conduit stimulates increased acetyl-CoA disposal through the TCA cycle, increas-
ing gluconeogenesis and export to the cytoplasm for DNL. These changes partly reflect the alterations encountered in NAFLD, in which the liver exhibits 
increased esterification to and lipolysis from lipid droplets, increased β-oxidation of fatty acids, increased terminal oxidation, and increased gluconeogen-
esis, but diminished ketogenesis relative to the availability of fat. In the extreme circumstance of ketogenic insufficiency and a high-fat load (right panel), 
β-oxidation–derived acetyl-CoA sequesters CoASH. This disrupts the TCA cycle, and in the setting of increased DNL, ultimately triggers hepatic injury and 
inflammation. Arrow thicknesses reflect relative changes through enzymatic reactions among panels rather than between reaction pathways within a panel. 
While proportional contributions of pyruvate carboxylase (PC) and PDH fluxes to the pyruvate fate are dynamic in states of feeding and fasting, both fluxes 
occur simultaneously in both physiological states (86, 87) and are likely to be influenced by insufficient ketogenesis. ME, malic enzyme.
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insufficient expression of the enzymatic mediators of fatty acid 
oxidation and gluconeogenesis, underlies the observed defect in 
fatty acid–stimulated glucose production in the setting of keto-
genic insufficiency.
Because the induction of gluconeogenesis by fatty acids is 
dependent on the NADH and ATP generated through the TCA 
cycle (16, 42, 43), we hypothesized that the failure of mitochondrial 
fatty acids to stimulate gluconeogenesis in the absence of ketogen-
esis could be mechanistically linked to a failure to couple β-oxida-
tion of fatty acids to their terminal oxidation via the TCA cycle. To 
determine whether there were abnormalities of TCA cycle func-
tion in the livers of HMGCS2 ASO–treated mice, we used NMR to 
quantify TCA cycle intermediate–pool concentrations in perfused 
livers of control and HMGCS2 ASO–treated mice. While tissue 
α-ketoglutarate (α-KG) concentrations were normal in the livers 
perfused in the absence of octanoate, inclusion of this fatty acid in 
the perfusion buffer increased concentrations of α-KG by 2-fold in 
HMGCS2 ASO–treated livers (0.75 ± 0.08 nmol/mg tissue vs. 0.34 
± 0.08 nmol/mg tissue in control livers perfused with octanoate, 
n = 7–8/group, P = 0.0032; Figure 6D). Perfusion with octanoic acid 
also increased hepatic concentrations of glutamate, an equilibrium 
partner of α-KG, by 2-fold, but significantly decreased hepatic suc-
cinate concentrations by 43% in HMGCS2 ASO–treated livers (99.9 
± 12.9 pmol/mg tissue vs. 162.8 ± 20.1 pmol/mg tissue in controls, 
P < 0.01, n = 7–8/group; Figure 6, E and F). These derangements of 
TCA cycle intermediate concentrations were not linked to redox 
potential alterations, as NAD+, NADH, NADt concentrations, and 
NAD+/NADH ratios in ketogenesis-insufficient livers perfused in the 
absence (Figure 6G) or presence (Figure 6H) of octanoate were not 
different from those of control animals. Taken together, these data 
suggest that ketogenic insufficiency disrupts TCA cycle homeostasis 
and gluconeogenesis through mechanisms independent of altered 
redox potential.
The NMR findings from perfused livers of ketogenesis-insuf-
ficient mice suggest a block at the TCA cycle reaction catalyzed 
by the α-KG dehydrogenase complex (OGDC). Since intrinsic 
OGDC activity was normal in isolated mitochondrial respiration 
assays using glutamate as a substrate (data not shown), the redox 
potential was normal in perfused livers, and oxidative decarboxy-
lation of α-KG to succinyl-CoA requires free CoASH, we tested 
the hypothesis that CoASH becomes limiting in ketogenesis-
insufficient livers exposed to excess fat by quantifying CoASH 
concentrations in unperfused and perfused livers of ASO-treated 
mice. While HMGCS2 ASO treatment did not alter CoASH con-
centrations in unperfused livers of standard chow diet–fed mice 
or in livers perfused in the absence of octanoate, hepatic CoASH 
concentrations were decreased by 60% in HMGCS2 ASO–treated 
livers perfused with octanoic acid (40.7 ± 14.4 pmol/mg tissue vs. 
106.6 ± 24.3 pmol/mg tissue in controls, P = 0.035, n = 8/group; 
Figure 7A). The fatty acid–induced depletion of CoASH observed 
in HMGCS2 ASO–treated livers occurred despite normal expres-
sion of Pank1a and increased expression of Pank1b (1.0 ± 0.02 
vs. 2.5 ± 0.6, P = 0.04, n = 8–10/group), whose products phos-
phorylate pantothenic acid in the first step of de novo CoASH 
biosynthesis (Figure 7B). Consistent with the octanoate-induced 
derangements of TCA cycle intermediates and CoASH depletion 
in livers of standard chow diet–fed HMGCS2 ASO–treated mice, 
acyl-CoA species produced in the fatty acid elongation pathway 
described in the Kyoto Encyclopedia of Genes and Genomes 
(KEGG) (38, 39) and identified 14 features whose mass-to-charge 
value matched 1 or more of these species (Supplemental Table 
5). The summed ion count of each of these acyl-CoA groups, rep-
resenting the total abundance of a species in all of its observed 
labeled forms, was markedly increased in HMGCS2-deficient liv-
ers, suggesting increased flux through the DNL pathway (Figure 5, 
C and D). To confirm that these identified acyl-CoA species were 
not differentially labeled by [13C]pyruvate, bioinformatics analysis 
using software that we recently developed (40) revealed that these 
compounds were not labeled differently in ketogenesis-insuffi-
cient animals compared with those in controls, again supporting 
that augmented acyl-CoA pools cannot simply be attributed to 
increased labeling, but instead indicate increased pool sizes. More-
over, terminal oxidation of [13C]pyruvate in the TCA cycle was rel-
atively diminished in the livers of ketogenesis-insufficient animals, 
as revealed by quantification of the fractional 13C enrichment of 
glutamate from [13C]pyruvate by NMR (12.8 ± 1.9% 13C enrichment 
of glutamate vs. 20.1 ± 2.7% in controls, n = 7–8/group, P < 0.05; 
Figure 5E); 13C enrichment of glutamate serves as a quantitative 
surrogate for [13C]acetyl-CoA terminal oxidation (41). However, we 
found that steady-state acetyl-CoA concentrations in whole liver 
extracts were not altered in ketogenesis-insufficient animals (Fig-
ure 5F). Collectively, these findings indicate that insufficient keto-
genesis triggers a redistribution of the total mitochondrial acetyl-
CoA pool toward export and de novo lipid synthesis.
Ketogenic insufficiency sequesters free CoASH. To better under-
stand the shift from hyperglycemia in chow-fed ketogenesis-insuf-
ficient mice to hypoglycemia upon high-fat feeding, we quantified 
gluconeogenesis from [13C]pyruvate in the presence or absence of 
octanoic acid in perfused livers of ASO-treated mice fed a stan-
dard low-fat chow diet. Octanoic acid is a medium-chain fatty acid 
that enters the mitochondrial matrix independently of carnitine 
palmitoyltransferase 1 (CPT1) and rapidly stimulates mitochon-
drial β-oxidation and gluconeogenesis (19). Consistent with the 
observation of hyperglycemia in standard chow diet–fed HMGCS2 
ASO–treated mice (Supplemental Figure 2G), we found that basal 
gluconeogenesis from pyruvate in the absence of octanoic acid 
was increased in the livers of ketogenesis-insufficient animals 
(15.2 ± 2.1% 13C enrichment of glucose vs. 9.0 ± 1.0% in controls, 
n = 7–8/group, P = 0.015; Figure 6A). Because total hepatic glu-
cose concentrations did not differ between groups (Figure 6B), 
the increased enrichment reflects increased production from 
pyruvate. As expected, the addition of unlabeled octanoic acid to 
the perfusion buffer stimulated gluconeogenesis in the livers of 
control animals (Figure 6A, white bars), but in contrast, HMGCS2 
ASO–treated livers perfused with octanoic acid did not increase 
gluconeogenesis and, in fact, exhibited decreased 13C-glucose 
enrichment compared with that seen in control livers (11.8 ± 1.7% 
13C enrichment of glucose vs. 17.6 ± 1.3% in controls, n = 7–8/group, 
P = 0.018; Figure 6A), without altering total glucose pools (Figure 
6B). We observed the inability of octanoic acid to stimulate glu-
cose production in HMGCS2 ASO–treated livers despite increased 
mRNA abundances of Ppara, Aco, Cpt1a, Ppargc1a, Pck1, and Me2 
and normal mRNA abundances of Acadm, Fgf21, and G6Pc in liver 
(Figure 6C), suggesting that a metabolic mechanism, rather than 
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acids with other organs that may require it, particularly in states 
of diminished carbohydrate availability. However, this model nei-
ther accounts for the hepatocyte’s need to support ketogenesis for 
its own metabolic homeostasis, nor considers the importance of 
basal hepatic ketogenesis in physiological states that are not con-
sidered “ketogenic” (i.e., carbohydrate restricted). Ours are the 
first studies to our knowledge to demonstrate a critical role for 
hepatic ketogenesis in the normal absorptive state and in preven-
tion of metabolic decompensation in the setting of overnutrition. 
We found that when ketogenic capacity is markedly impaired, 
an HFD triggers a cascade of events that culminates in hepatic 
injury and inflammation. These observations are underscored 
by our recent studies of germline SCOT-KO mice, which cannot 
terminally oxidize ketone bodies in any tissue. These mice exhibit 
hyperketonemic hypoglycemia and die within 48 hours of birth in 
a manner that phenocopies human sudden infant death syndrome 
(SIDS) (32). Despite the fact that SCOT is normally excluded from 
hepatocytes, livers of SCOT-KO mice develop abnormalities of 
hepatic fatty acid oxidation, pyruvate metabolism, redox poten-
tial, and even ketogenesis (22, 33). In stark contrast to the severe 
metabolic derangements and SIDS-like phenotype observed in 
neonatal SCOT-KO mice, mice that cannot oxidize ketone bodies 
selectively within neurons, cardiomyocytes, or skeletal myocytes, 
which comprise the 3 greatest consumers of ketone bodies, survive 
the neonatal period and starvation in adulthood (34). Together, 
these results indicate that coordination of ketogenesis and ketone 
body oxidation may be of greater importance to preserve the 
dynamic intermediary metabolic network in the liver than it is to 
provide energy to extrahepatic tissues.
Our data are consistent with a model (Figure 8) in which the 
metabolic consequences of ketogenic insufficiency occur along a 
continuum of maladaptive consequences. On a standard diet and 
in the absence of a high lipid load, the modest amount of acetyl-
CoA generated from endogenous fats that would normally proceed 
through ketogenesis is instead terminally oxidized in the TCA cycle, 
generating the ATP and NADH to support increased gluconeogen-
esis from pyruvate, thereby predisposing to mild hyperglycemia. In 
addition, the total hepatic mitochondrial pool of acetyl-CoA, which 
is predominantly derived from β-oxidation of acyl-CoAs and by 
decarboxylation of pyruvate, is maintained at a homeostatic concen-
tration by eventual conversion to acetylcarnitine and by exportation 
as citrate for synthesis of de novo lipids. Given that gluconeogen-
esis is indirectly stimulated by mitochondrial acetyl- CoA through 
allosteric activation of pyruvate carboxylase (44), adult- onset loss 
of ketogenesis may reset the basal rate of gluconeogenesis through 
a shift toward increased mitochondrial acetyl-CoA. Therefore, 
even in the nonlipolytic absorptive state, in which dietary carbohy-
drates are abundant, hepatic ketogenesis influences glycemia and 
hepatic lipid metabolism through modulation of acetyl- CoA fates. 
These experimental conditions, in which ketogenesis is severely 
deficient but exogenous fat delivery is low, may be representative 
of more clinically relevant states in which ketogenesis is modestly 
suppressed, but exogenous fat delivery (from intake) is elevated. 
Acetyl-CoA metabolism has recently emerged as a key regulator of 
numerous cellular processes and signaling pathways, and acetyl-
CoA has different roles depending on its site of synthesis or accu-
mulation. Cytosolic and/or nuclear acetyl-CoA regulate protein 
unperfused livers of HMGCS2 ASO–treated mice fed a 60% 
HFD displayed increased glutamate concentration (2.6 ± 0.4 vs. 
1.1 ± 0.1 nmol/mg tissue in controls, P = 0.018, n = 4–5/group), a 
trend toward decreased succinate concentration, and decreased 
hepatic CoASH concentration (28.4 ± 11.5 pmol CoASH/mg tis-
sue vs. 103.1 ± 32.6 in controls, P = 0.049, n = 8/group; Supple-
mental Figure 6, A–C). Taken together, these results suggest that 
ketogenic insufficiency in the setting of high-fat delivery depletes 
free CoASH and thereby impairs TCA cycle function, which fur-
ther inhibits entry of acetyl-CoA and also favors increased accu-
mulation of short-chain acylcarnitines.
To determine whether supplementation of the CoASH pre-
cursors pantothenic acid (vitamin B5) and cysteine could restore 
glucose production and normalize TCA cycle intermediate con-
centrations in HMGCS2 ASO–treated livers, we perfused the liv-
ers of HMGCS2-deficient and control animals with exogenous 
octanoate and CoASH precursors. While inclusion of pantothenic 
acid and cysteine with [13C]lactate, [13C]pyruvate, and unlabeled 
octanoic acid during a 15-minute perfusion failed to normalize 
gluconeogenesis in HMGCS2 ASO–treated livers (Figure 7C, left), 
prolonged repletion of CoASH precursors by perfusing indepen-
dent livers with pantothenic acid and cysteine for 45 minutes 
prior to perfusion with [13C]lactate and [13C]pyruvate, unlabeled 
octanoic acid, pantothenic acid, and cysteine for 15 minutes 
normalized 13C-glucose enrichment (Figure 7C, right). Total 
hepatic glucose concentrations did not differ between control 
and HMGCS2 ASO–treated livers in either perfusion experiment 
(Supplemental Figure 7). Moreover, preperfusion with CoASH 
precursors attenuated the expansion of the α-KG and glutamate 
pools in HMGCS2 ASO–treated livers, with preperfused HMGCS2 
ASO–treated livers exhibiting a 29% decrease in α-KG concentra-
tions and a 43% decrease in glutamate concentrations compared 
with those in HMGCS2 ASO–treated livers that were not preper-
fused with CoASH precursors (n = 5–7/group, P < 0.05 for α-KG, 
and P < 0.001 for glutamate; Figure 7, D and E). Inclusion of pan-
tothenic acid and cysteine also normalized succinate concentra-
tions in the livers of HMGCS2 ASO–treated mice, irrespective of 
the length of the perfusion (Figure 7F). Finally, CoASH precursor 
supplementation with either method of perfusion normalized the 
steady-state concentrations of free CoASH in the livers of keto-
genesis-insufficient mice compared with those in control livers 
(Figure 7G). Taken together, these results mechanistically link 
the HFD-induced hypoglycemia and fat-induced impairment of 
hepatic gluconeogenesis we observed in ketogenesis-insufficient 
mice to CoASH depletion and inhibition of the α-KG dehydroge-
nase reaction of the TCA cycle.
Discussion
Hepatic ketogenesis is activated when fatty acids are plentiful, car-
bohydrates are in short supply, and/or circulating insulin concen-
trations are low (17–21). This spillover pathway converts β-oxida-
tion–derived acetyl-CoA, produced in excess of the hepatocyte’s 
own energy needs, into ketone body intermediates, thus diverting 
carbon away from the hepatic TCA cycle and providing extrahe-
patic tissues with a readily oxidized fuel source. This paradigm 
forms an “altruistic” model of ketone body metabolism, in which 
the hepatocyte shares “precatabolized” energy obtained from fatty 
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tor of fatty acid oxidation, peroxisome proliferator–activated 
receptor α (PPARα) (60, 61). In at least 1 immortalized hepatoma 
cell line, HMGCS2 expression was required for fatty acid oxi-
dation (62). In contrast, our observations reveal a robust induc-
tion of several classical PPARα targets in the absence of hepatic 
HMGCS2, and 2 lines of evidence support robust fatty acid oxi-
dation in the livers of HMGCS2-deficient mice: (a) long-chain 
acylcarnitines did not accumulate, and (b) the contribution of 
pyruvate to the acetyl-CoA oxidized in the TCA cycle was rela-
tively diminished. Moreover, the increased gluconeogenesis we 
observed in the livers of ketogenesis-insufficient animals under 
low-fat-diet conditions strongly suggests normal or elevated 
TCA cycle flux. Together, these data indicate an increase in the 
relative contribution of endogenous fatty acids to the TCA cycle 
and are consistent with metabolic flux that is driven primarily 
by the principles of mass action and enzymatic allostery, with 
coordinated responses at the level of gene expression that reflect 
adaptations to diminished disposal of acetyl-CoA through keto-
genesis. Whether HMGCS2 serves as a PPARα coactivator in vivo 
remains to be determined, as does whether the prospective lig-
ands produced via DNL in ketogenesis-insufficient animals serve 
as potential PPARα activators (63).
Genome-wide association and exome sequencing studies 
have revealed relationships between numerous genes encod-
ing mediators of lipid metabolism and NAFLD/NASH (64, 65). 
Variations in the genes encoding ketogenic mediators, including 
HMGCS2, HMG-CoA lyase, and βOHB dehydrogenase, have 
not yet emerged as independent predictors of liver pathology 
or diabetes. While HMGCS2 deficiency is very rare in humans, 
total HMGCS2 enzymatic deficiency is associated with pediat-
ric hypoketonemic hypoglycemia and hepatic steatosis (66–71). 
Importantly, our studies of neonatal mice revealed that partial 
loss of HMGCS2 activity caused marked hepatic steatosis vastly 
out of proportion to the diminution in neonatal ketosis, but did 
not result in neonatal hypoglycemia or failure to thrive. These 
findings raise the possibility that genetic polymorphisms yielding 
insidious and subtle ketogenic defects could latently predispose 
to fatty liver disease and attest to the critical fine-tuning role that 
hepatic ketogenesis plays in the regulation of hepatic glucose and 
lipid metabolism.
No current pharmacological therapies directly treat NAFLD 
or NASH, which are managed instead through lifestyle modifi-
cations such as weight loss and treatment of dyslipidemia and 
hyperglycemia (72). A variety of agents are at various stages of 
investigation, including compounds targeting oxidative stress, 
nuclear receptor activators, insulin sensitizers, modifiers of dys-
lipidemias, and immunomodulatory agents (3, 6). Ketogenesis has 
not yet been considered as a therapeutic target. Obese humans 
and mice exhibit diminished whole-body ketone body turnover 
(26, 29). Furthermore, circulating ketone body concentrations 
are generally decreased in obese humans (24, 25, 27) and serve as 
predictive biomarkers for conversion to type 2 diabetes in patients 
with impaired fasting glucose (73). Compared with BMI-matched 
individuals, obese patients with NAFLD exhibit increased hepatic 
glucose production and TCA cycle flux without augmented keto-
genesis (28). DNA methylation, nuclear receptor–mediated tran-
scriptional activation, and reversible succinylation, acetylation, 
acetylation (45, 46), autophagy (47, 48), and histone acetylation and 
subsequent transcriptional changes (49, 50). Future experiments 
will explore the scope of signaling consequences of insufficient 
ketogenesis, how altered acetyl-CoA metabolism may mediate 
those effects, and how discrete acetyl-CoA pools target distinct 
fates based on the original source of acetyl-CoA. Because the reten-
tion time window harboring the majority of dysregulated LC/MS 
features in the livers of ketogenesis-insufficient animals included a 
large number of lipophilic molecules, these approaches may reveal 
previously unsuspected connectivity among hepatic ketogenesis, 
acetyl-CoA, lipid metabolism, and cell signaling.
The convergence of ketogenic insufficiency with either acute 
delivery of fatty acids or chronic exposure to a “nonketogenic” 
(not carbohydrate-restricted) HFD results in additional metabolic 
sequelae (Figure 8, right) that uncouple increased fat availability 
from increased gluconeogenesis through mechanisms that can 
be linked to sequestration of free CoASH, a critical by-product of 
ketogenesis. Therefore, despite presumably increased allosteric 
activation of pyruvate carboxylation, gluconeogenesis becomes 
impaired through mechanisms that can be linked to a diminished 
availability of CoASH. CoASH liberated by ketogenesis is critical 
in states of high-fat delivery, in part by serving as a substrate for 
the α-KG dehydrogenase reaction, to support homeostatic TCA 
cycle function, which in hepatocytes is a key regulator of glucone-
ogenesis. Intriguingly, the total hepatic triacylglycerol pool did not 
expand in the livers of HFD-fed ketogenesis-insufficient animals 
compared with that observed in controls, suggesting either rela-
tive limitation of substrate (e.g., glycerol), impairment of cytoplas-
mic acylglycerol transferase or phosphatidate phosphatase activ-
ity, or entry of acyl chains into other synthetic pathways.
Ketogenesis-insufficient mice fed an HFD developed steatosis 
equivalent to that seen in controls, but only ketogenesis-insufficient 
mice developed severe inflammation, suggesting that of the 2 major 
NAFLD subtypes, simple steatosis and NASH, impaired ketogene-
sis may be an important determinant of NASH (1). Other forms of 
hepato cellular injury are also associated with decreased CoASH con-
centrations. In acute acetaminophen toxicity, CoASH levels decrease 
simultaneously with decreasing HMGCS2 enzymatic activity (51, 
52). Potentially fatal valproic acid therapy–induced hepatic dysfunc-
tion, which is associated with impaired β-oxidation of fatty acids 
and ketogenesis due to sequestration of CoASH into poorly metab-
olized valproyl CoA, can be prevented by administration of CoASH 
precursors (53, 54). In rodents, hepatic CoASH concentrations 
decrease in response to an HFD (55), while the concentration of pan-
tothenic acid actually increases (56), suggesting that hepatic CoASH 
homeostasis is dysregulated in obesity. De novo CoASH synthesis is 
required for life in mice, and impaired CoASH synthesis is associated 
with fasting-induced hepatic steatosis (57, 58). CoA sequestration, 
toxicity, or redistribution (CASTOR) encompasses hereditary and 
acquired diseases of impaired CoASH liberation, including defi-
ciencies of hepatic ketogenesis (59). Despite the increasing burden 
of evidence for the contribution of CoASH homeostasis to hepatic 
function, the role of therapies that support de novo CoASH synthesis 
in obesity and NAFLD remains relatively unexplored.
HMGCS2 has been proposed to possess a “moonlighting” 
role as a transcriptional regulator that translocates to the nucleus 
and serves as a coactivator for a master transcriptional regula-
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liver tissue. For CoASH, approximately 75 mg of tissue was homoge-
nized using a glass-on-glass dounce in ×10 volume of ice-cold deion-
ized water. Homogenates were spun at 15,000 g for 20 minutes at 
4°C. Supernatants were transferred to clean tubes on ice and were 
then dehydrated using a rotary speed vacuum. Tissue pellets were 
resuspended to 2 mg/μl, and 20 mg of tissue (10 μl) were loaded 
into a 96-well plate for CoASH and long-chain acyl-CoA concen-
trations using an enzyme-linked colorimetric assay (BioVision). 
NAD+(H) concentrations were measured using an enzyme-cycling 
colorimetric assay (BioVision).
Histology. Immediately following sacrifice, liver specimens were 
collected and fixed in 10% neutral buffered formalin (Fisher Scien-
tific) or cryopreserved in optimal cutting temperature compound 
(O.C.T.; Tissue-Tek).
Gene expression analysis. Quantification of gene expression was 
performed by real-time reverse-transcriptase quantitative PCR 
using the ΔΔCt approach, as previously described (31), normalizing 
to Rpl32, using the primer sequences listed in Supplemental Table 6.
Immunoblotting. Immunoblots to detect HMGCS2 (rabbit anti-
mHMGCS; Santa Cruz Biotechnology Inc.), HMGCS1 (rabbit anti-
HMGCS1; Thermo Fisher Scientific), and actin (rabbit anti-actin; Sig-
ma-Aldrich) were performed as previously described (32).
Liver perfusions. Mice were fasted for 4 hours prior to perfusion, 
with the exception of mice that were perfused after an overnight 
fast as indicated in the Results. Ten minutes prior to each liver per-
fusion, mice received an i.m. injection of heparin (100 U). Mice 
were then anesthetized with 10 μl of sodium pentobarbital (Fatal-
Plus, 390 mg/ml) administered i.p. Once fully anesthetized (after 
approximately 5 minutes), the abdomen was sprayed with 70% 
ethanol, and the mouse was placed on a surgical platform within 
a large reservoir to contain run-off buffer and body fluids. A trans-
verse incision was made through the skin, fascia, and muscular 
layers of the lower abdomen. A lateral sagittal incision was made 
on each side of the body, exposing the abdominal contents. A sec-
ond transverse incision was made inferiorly to the right kidney and 
toward the dorsal aspect of the mouse to allow the perfusion buffer 
and body fluids to drain from the abdomen. The portal vein was then 
exposed by gently moving the intestines laterally toward the left 
body wall. A suture needle was threaded under the portal vein and 
tied loosely. Next, the portal vein was cannulated with a 24-gauge 
catheter needle, the needle was withdrawn, and tubing with buffer 
was reconnected to the catheter. The abdominal aorta and inferior 
vena cava were cut, and the catheter was firmly tied into the portal 
vein. Finally, the beating heart was exposed by cutting through the 
diaphragm and thorax. The right atrium was cut to prevent recircu-
lation of buffer to the liver and to terminate perfusion to the brain. 
All livers were perfused with an oxygenated Krebs-Henseleit bicar-
bonate buffer (118 mM NaCl, 25 mM NaHCO3, 4.7 mM KCl, 0.4 
mM KH2PO4, 2.5 mM CaCl2, 1.22 mM MgSO4-7•H2O, pH 7.4) and 
warmed to 37°C with a counter-current heat-exchange circuit and 
a recirculating water bath at a rate of 8 ml/minute using a peristal-
tic pump for 15 minutes, unless otherwise noted. At the end of the 
perfusion, the liver was freeze-clamped and rapidly frozen in a bath 
of liquid nitrogen. Tissue was stored at –80°C until further process-
ing. For measurements of ketogenesis in perfused livers, the buffers 
contained sodium [1,2,3,4-13C4]octanoate (0.2 mM), sodium lactate 
(1.5 mM), and sodium pyruvate (0.15 mM). For all measurements 
and phosphorylation all exert multitiered transcriptional and 
posttranslational regulation of Hmgcs2 expression and HMGCS2 
enzymatic activity to coordinate ketogenesis during diverse phys-
iologic contexts (17, 74–78). Pharmacological approaches that 
regulate enzymatic mediators of lysine deacylation (45) may rep-
resent a promising avenue for modulating HMGCS2 and ketogen-
esis, which may serve as a novel therapeutic target in fatty liver 
disease and obesity.
Methods
Further information can be found in the Supplemental Methods.
Animals. All adult mice studied were males on a C57BL/6N X 
C57BL/6J hybrid background. For neonatal experiments, both sexes 
were studied. Unless otherwise noted, mice were maintained on a 
standard low-fat chow diet, in which 13% of the calories were from 
fat, 25% from protein, and 62% from carbohydrates (LabDiet 5053), 
and were given autoclaved water ad libitum. Lights were off between 
1800 and 0600 in a room maintained at 22°C. For all adult mouse 
experiments, mice were housed on sawdust bedding in groups of 4 
to 5. ASO treatment was initiated in 6-week-old mice by i.p. injec-
tion (25 mg/kg) with murine Hmgcs2-targeted ASOs (ISIS 191229; 
5′-CTGTTTGTCACTGCTGGATG) or scrambled sequence control 
ASOs (ISIS 141923; 5′-CCTTCCCTGAAGGTTCCTCC) biweekly 
for 4 weeks. For HFD studies, after 2 weeks of ASO treatment, mice 
were maintained for 8 weeks on either an HFD, in which 60% of cal-
ories were from fat, 20% from protein, and 20% from carbohydrates 
(D12492; Research Diets), or, in separate cohorts, a diet (110290; 
Harlan Teklad) in which 40.7% of calories were from fat (lard and 
milk fat, 52% saturated, 41% monounsaturated, and 7% polyunsat-
urated [0% trans] fatty acids), 19% from protein, and 40.3% from 
carbohydrates (sucrose, 183 g/kg and cornstarch, 140 g/kg), during 
which time biweekly ASO administration continued. For the neo-
natal experiments, ASOs were administered (25 mg/kg) s.c. daily, 
beginning on the second day of life and until P12. Pups were marked 
on the abdomen daily with a permanent marker to enable longitu-
dinal monitoring of body weight and blood glucose. Marking also 
enabled control and HMGCS2 ASOs to be administered to different 
pups within the same litter, thus minimizing inter-litter variance of 
metabolic parameters.
Measurements of food intake, body weight, and body composition. 
Food intake was monitored beginning on day 1 of ASO treatment 
for each cage of mice. Food intake was measured biweekly for the 
duration of each experiment and normalized to the number of mice 
per cage and the number of days between measurements, which was 
always 3 or 4 days. Mice were also weighed biweekly at the onset of 
all experiments. Body weight and body composition were recorded 
following a 4-hour fast (1000–1400), after which food was returned 
immediately. The percentage of body fat and lean body mass was 
quantified in awake adult animals using an EchoMRI instrument 
(Echo Medical Systems).
Plasma metabolite quantification. Serum and blood metabolic 
parameters were measured in samples collected following a 4-hour 
fast, as described previously (31).
Tissue metabolite quantification. Hepatic TAG concentrations 
were quantified biochemically using a Folch extract of liver, as 
described previously (79). Tissue CoASH, NAD+, and NADH con-
centrations were measured in freeze-clamped and biopulverized 
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The features table was then processed in R to search for features 
whose m/z matched to species in the fatty acid elongation pathway 
as detailed in KEGG (38, 39). Consideration was given for enrich-
ment of 13C labels in each species by grouping features with similar 
retention times (<0.2-minute range) and whose m/z values were off-
set from the mass of an unlabeled acyl-CoA species by whole-num-
ber multiples of the mass difference between 12C and 13C (1.00335 
amu). Where multiple groups of such features, known as isotopo-
logs, matched to a single acyl-CoA species, a selection of the sin-
gle group to which the species was assigned was made based on the 
following criteria: (a) minimum of 3 isotopologs represented in the 
group; (b) statistically significant difference (P < 0.05, by Student’s 
t test) in abundance between control and HMGCS2-deficient sam-
ples for at least 1 isotopolog in the group; and (c) proximity of the 
group’s retention time to that of other groups assigned to acyl-CoAs, 
given that these species are all chemically similar and are expected 
to elute close to one another. Where a single group matched to mul-
tiple potential acyl-CoA species, all possible identities are listed 
in Supplemental Table 5, but for the plot in Figure 5D, the 978 m/z 
group was assigned to tetredecanoyl-CoA due to the lower number 
of 13C labels that would be incorporated into that molecule. The 
identity of acetyl-CoA was verified by using an acetyl-CoA standard 
(Sigma-Aldrich) dissolved in 1:1 ACN/water, with observation of 
808.1140 and 808.1127 m/z unique peaks at retention times of 37.9 
and 40.0 minutes, respectively. The summed intensities of these 
peaks and their associated isotopolog groups were then determined 
in liver extracts of control and HMGCS2 ASO–treated animals.
To quantify differential 13C-labeling of identified features, the 
mzXML files described above were processed in R using XCMS (84) 
and X13CMS (40), with the latter being modified to detect differences 
in 13C enrichment patterns of metabolites extracted from [3-13C]pyru-
vate/lactate-labeled control versus HMGCS2-deficient livers (in con-
trast to the usual usage, in which differences are detected between 
unlabeled and labeled samples of the same biological type). Enrich-
ment patterns are defined as the distribution of metabolite abun-
dance among the various isotopolog forms of a particular metabolite. 
Differences in patterns were defined as changes in the shape of this 
distribution between biological sample types, e.g., control versus 
ketogenesis insufficient.
Mitochondrial isolation and respiration. Mitochondrial isolation 
and respiration studies were conducted and assessed as described 
previously (79, 85).
Statistics. Analyses were performed with GraphPad Prism 5.0 
software (GraphPad Software). Unpaired 2-tailed Student’s t tests 
and 2-way ANOVA, with Bonferroni’s correction to correct for mul-
tiple comparisons, were used as appropriate, as indicated within the 
text and figure legends. Data are presented as the means ± SEM unless 
otherwise indicated. A P value of less than 0.05 was considered signifi-
cant, except for the LC/MS studies, in which a P value of less than 0.01 
was considered significant.
Study approval. All experiments were conducted using protocols 
approved by the Animal Studies Committee of Washington University.
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